Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. Competitors

1,313 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GPCRStructure Therapeutics, Inc. Sponsored ADR$16.13$1.15B-4.13-53.03%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGPCRUnlock the GPCR top-analyst price target with TipRanks Premium
LXRXLexicon Pharmaceuticals$1.53$681.21M-10.5315.91%Strong BuyUnlock the LXRX analyst price target with TipRanks PremiumGPCR vs LXRXUnlock the LXRX top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$24.77$3.16B-4.59-27.72%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumGPCR vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$49.55$2.46B-16.1983.31%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumGPCR vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
SEPNSepterna, Inc.$38.61$1.84B-29.9362.43%Strong BuyUnlock the SEPN analyst price target with TipRanks PremiumGPCR vs SEPNUnlock the SEPN top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.02$1.43B-3.64-57.62%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGPCR vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GPCRStructure Therapeutics, Inc. Sponsored ADR16.13-19.17-54.31%
LXRXLexicon Pharmaceuticals1.530.117.75%
VKTXViking Therapeutics24.77-9.88-28.51%
MBXMBX Biosciences, Inc.49.5518.3158.61%
SEPNSepterna, Inc.38.6110.1035.43%
KLRAKailera Therapeutics, Inc.11.02-14.98-57.62%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts